Crossover Study to Assess the Safety and Pharmacokinetic of Pegylated Somatropin(PEG Somatropin) in GHD Children
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
The purpose of the phase 1 study is to assess the safety and pharmacokinetics of PEG
somatropin, which administered once per week, compared with the daily used somatropin, and to
evaluate the safety and possibility to replace daily used somatropin.